| __timestamp | Ascendis Pharma A/S | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 612613000000 |
| Thursday, January 1, 2015 | 9415000 | 650773000000 |
| Friday, January 1, 2016 | 11504000 | 619061000000 |
| Sunday, January 1, 2017 | 13482000 | 628106000000 |
| Monday, January 1, 2018 | 25057000 | 717599000000 |
| Tuesday, January 1, 2019 | 48473000 | 964737000000 |
| Wednesday, January 1, 2020 | 76669000 | 875663000000 |
| Friday, January 1, 2021 | 160180000 | 886361000000 |
| Saturday, January 1, 2022 | 221227000 | 997309000000 |
| Sunday, January 1, 2023 | 264410000 | 1053819000000 |
| Monday, January 1, 2024 | 284545000 | 1053819000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a leader in the global market, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, reflecting a 72% rise over the decade. This trend underscores Takeda's commitment to expanding its market presence and operational efficiency.
Conversely, Ascendis Pharma A/S, a rising star in the biotech sector, has exhibited a more dynamic growth trajectory. Starting with modest SG&A expenses in 2014, Ascendis has seen a dramatic increase, reaching 264 million euros by 2023. This represents an astounding 4,100% surge, highlighting its aggressive expansion and investment in innovation. The data reveals a tale of two strategies: Takeda's steady growth versus Ascendis's rapid ascent.
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation